The site is currently unavailable, please come back later.
Managing Director – Accenture Healthcare Technology France & BeNeLux
Laurent Stefani is Executive Director in charge of Life Sciences, MedTech, Health & Health Insurance at Accenture where he covers all technology engagements with a particular focus on Cloud, Artificial Intelligence and Digital Transformation.
A graduate of the Ecole Polytechnique, the Ecole Nationale Supérieure des Télécommunications and the Universidad Politécnica de Madrid, Laurent Stefani has 18 years of experience in the healthcare industry in France and the United States.
Vincent Serra, 51, PhD in Immunology, is a seasoned executive with over 20 years of experience in biotechnology, particularly in the field of immunotherapy. He is the author of several patents and articles in peer-reviewed scientific publications in the field of vaccines. Prior to joining Neovacs as Chief Scientific Officer in January 2019, he was Head of External Innovation at Pierre Fabre, and Executive Director of its Innovation Fund. Vincent Serra has also served as Chief Scientific Officer, Chief Executive Officer and co-founder of various biotechnology companies. In addition, he has established numerous licensing agreements during his career, developed various products through clinical development and participated in the creation and IPO of Abivax.
As President and Managing Partner of Jolt Capital, Jean Schmitt has led Jolt’s vision and development since 2012. The impetus behind the founding of Jolt was Jean Schmitt’s realization that the best risk-adjusted returns usually come from late-stage and growth cycles in companies that no longer face technology risk.
Prior to founding Jolt Capital, Jean Schmitt was a Managing Partner at Sofinnova Partners, leading the IT practice with a focus on the telecommunications and wireless markets.
Prior to his investment career, he was CEO and founder of 4 companies with successful exits, including SLP InfoWare, which he sold to Gemplus (now Gemalto, XPAR:GTO) in 2000 for $60 million, then became VP Telecom Solutions & Applications for the larger group.
Jean Schmitt is a graduate of Télécom ParisTech and holds a DESS in Artificial Intelligence. He is a visiting professor at Telecom ParisTech and HEC Paris, former president of the International Venture Club and a member of Henkel’s Henkel X mentoring program.
After a doctoral thesis in Physics and 10 years of research, Suat Topsu obtained a position as University Professor in Quantum Physics at the University of Paris-Saclay in 2008. In 2012 he founded and ran a company based on an innovative telecommunication technology that came out of my lab, now known as LiFi. In 2018 he joined as Executive Chairman the Satt idfinnov (now Erganeo) to help through financial investments other Deeptech technologies to find their markets. He is also a director of several innovative companies and members of social and environmental foundations.
General practitioner, emergency physician and sports physician with experience in hospital and private practice. Strong tropism for innovation in health with a move to entrepreneurship via Kamet, venture inventor and builder. Co-founder and medical director of Qare, a B2C teleconsultation solution and service for all patients in order to improve access to quality care and enable doctors to evolve their practice. Strong belief in the European dimension of e-health, confirmed by the acquisition in 2021 of Qare by HealthHero, the European leader in e-health. Board member of HealtHero France, vice-president of LeT (Les entreprises de Télémédecine) and senior medical advisor for private equity and venture capital.
Hugo Brugière is a graduate of the Saint-Cyr military academy and of Sciences Po Paris. A serial entrepreneur with more than twenty companies to his credit, he is particularly familiar with listed companies and restructuring/turnaround situations in which he has specialized for several years.
Aged 56, François Miceli holds a degree in biological engineering from the University of Paris XII – UPEC, is an alumnus of INSEAD (Corporate Finance, EE) and an auditor at IHEDN (Institut des Hautes Etudes de Défense Nationale, promotion Chevalier Bayard). He began his career at CLONATEC, an OHF group listed on the second market (now Euronext Growth), one of the very first biotech companies in France, where he held the position of product manager at the international level.
At the end of 1990, he joined IDEXX Laboratories Incorporated, an American company listed on NASDAQ, where he successively held the positions of Director Europe, Asia, Africa and Middle East of a business unit, then Managing Director of the French subsidiary IDEXX France S.A. and finally Managing Director and member of the Board of Directors of the Italian subsidiary IDEXX Laboratories Italia. During all these years spent within IDEXX, François Miceli was a member of the European Executive Committee.
In 1998, he joined SYNBIOTICS, a spin-off of Laboratoires MERIAL, as Director of International Operations before participating in the creation of LMD Pharma, a biotechnology start-up alongside venture capital funds, Banexi Ventures, LCF Rothschild, Siparex and Sofimac Partners Capital Investissement.
From October 2003 to February 2011, François was Chairman of the Board of Directors of the IMAXIO group, which specializes in infectious diseases (vaccines) and oncology, based in Lyon and Clermont-Ferrand. Since February 2009, he was also President and CEO of AXCELL Biotechnologies, a subsidiary of Imaxio. Under his presidency, IMAXIO won successively the 3rd Deloitte Fast 50 – Rhône-Alpes award in 2009 and the 2nd Deloitte Fast 50 – Rhône-Alpes award in 2010. Within the framework of the IMAXIO group, François Miceli was also Manager of EDULIS Technologie, a holding company for the management of technological assets of the Imaxio group.
After having been a Venture Partner and a member of the investment committee, François MICELI fully joined the private equity firm SOFIMAC PARTNERS in 2012 as Senior Partner. Managing Partner of SOFIMAC INNOVATION, a management company with 400 million euros in innovation capital. The latter has just merged with UI Investissement in which François is Senior Associate Director for Innovation.
François is also a director of Exeliom Biosciences, Ixaltis, Eurekam, Diabeloop, Igyxos, Axoltis, Aptys Pharmaceuticals, Cellmade, Isorg, Precilens and Futuragaia.
He is also a member of the Board of Directors of the M2CARE gas pedal specialized in health and nutrition and was President of the SAS INSERM TRANSFERT INITIATIVE
Until May 2009, François Miceli chaired the Supervisory Board ofERYtech Pharma S.A . listed on Euronext and he is a former administrator of the SIMV (Syndicat de l’Industrie du Médicament Vétérinaire). He is also AMF certified.
Loïc Poirier, CEO of ARCHOS, LOGIC INSTRUMENT and MEDICAL DEVICES VENTURE, joined ARCHOS in early 2005. Since then, the group has sold more than 20 million mobile products and achieved a cumulative turnover of more than €1.5 billion over the last fifteen years.
Prior to that, he served as CFO and Operations Director, Worldwide, Structure Division, at the automotive supplier Faurecia for more than two years and restructured the company’s industrial facilities.
From 2000 to 2003, he participated in the development of the CONSODATA group, leader in CRM, managing a strong organic growth but also acting in numerous acquisitions, in the United States, Canada and in Europe from London as Group CFO and actively contributed to the sale to the Telecom Italia group.
From 1992 to 2000, Loic progressed from Group Controller to Vice President Finance and Operations within the Packard Bell NEC group and co-managed the American subsidiary NEC Solutions, in California. Within the group, he had the opportunity to set up sales offices and factories in Asia, South Africa and Israel from design to marketing of laptops and other IT equipment.
Loïc Poirier is a graduate of Ipag Business School in France and of Insead (Executive Management Program).